Skip to main content Accessibility help
×
Home

Alternating cisplatinum and VAC ineffective in end stage squamous cell carcinoma of the head and neck

  • M. Z. Siodlak (a1), P. M. Stell (a1), J. A. Wilson (a1), J. A. Green (a1), R. S. Allison (a1), D. Adler (a1) and M. Squadrelli-Saraceno (a1)...

Abstract

Sixteen patients with end stage squamous cell carcinoma of the head and neck were admitted to a phase II study of alternating courses of cisplatinum (100mg/m2) and VAC (vincristine 1.4mg/m2, adriamycin 50 mg/m2, cyclophosphamide 750 mg/m2) given at three weekly intervals. Only two patients achieved a response (12 per cent). The median survival time was 62 days which is much the same as that of a similar group of patients who received no chemotherapy in a previous trial (70 days).

Copyright

Corresponding author

Prof. P. M. Stell, Royal Liverpool Hospital, Prescot Street, P.O. Box 147, Liverpool L69 3BX

References

Hide All
Bitran, J. D., Goldman, M. (1985) A phase II trial of cyclophosphamide and adriamycin in refractory squamous cell carcinoma of the head and neck. An effective salvage regimen. American Journal of Clinical Oncology, 8: 6164.
Decker, D. A., Drelichman, A., Jacobs, J., Hoschner, J., Kinzie, J., Loh, J., Wever, A., Al-Sarraf, M. (1983) Adjuvant chemotherapy with cisdiamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in stage III and IV squamous cell carcinoma of the head and neck. Cancer, 51: 13531355.
Feld, R., Evans, W. K., Coy, P., Hodson, I., MacDonald, A. S., Osoba, D., Payne, D., Shelley, W., Pater, J. L. (1987) Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. Journal of Clinical Oncology, 5: 14011409.
Goldie, J. H., Coldman, A. J. (1979) A mathematical model for relating the drug sensitivity of tumours to the spontaneous mutation rate. Cancer Treatment Reports, 63: 17271733.
Goldie, J. H., Coldman, A. J., Gudauskas, G. A. (1982) Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treatment Reports, 66: 439449.
Goodman, G. E., Crowley, J. J., Blasko, J. C., Livingston, R. B., Beck, T. M., Demattia, M. D., Bukowski, R. M. (1990) Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study. Journal of Clinical Oncology, 8: 3947.
Hong, W. K., Schaefer, S., Issell, B., Cummings, C., Luede, D., Bromer, R., Fofonoff, S., D'Aoust, J., Shapshay, S., Welch, J., Levin, E., Vincent, M., Vaughan, C., Strong, S. (1983) A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer, 52: 206210.
Johnson, J. T., Mayernick, D. G., Myers, E. N., Nolan, T. A., Schramm, V. L., Sigler, B. S., Wagner, R. L. (1987) Cisplatin-5-fluorouracil chemotherapy for advanced inoperable squamous carcinoma of the head and neck. Head and Neck Surgery, 9: 336340.
Kartner, N., Ling, V. (1989) Multidrug resistance in cancer. Scientific American March, 2633.
Miller, A. B., Hoogstraten, B., Staquet, M., Winkler, A. (1981) Reporting results of cancer treatment. Cancer, 47: 207214.
Morton, R. P., Rugman, F., Dorman, E. B., Stoney, P. J., Wilson, J. A., McCormick, M. A., Veevers, A., Stell, P. M. (1985) Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomized factorial phase III controlled trial. Cancer Chemotherapy and Pharmacology, 15: 283289.
The Liverpool Head and Neck Oncology Group (1990) A phase III randomized trial of cisplatinum, methotrexate, cisplatinum + methotrexate, and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. British Journal of Cancer, 61: 311315.

Alternating cisplatinum and VAC ineffective in end stage squamous cell carcinoma of the head and neck

  • M. Z. Siodlak (a1), P. M. Stell (a1), J. A. Wilson (a1), J. A. Green (a1), R. S. Allison (a1), D. Adler (a1) and M. Squadrelli-Saraceno (a1)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed